Astrana Health price target raised to $86 from $67 at Baird

Baird raised the firm’s price target on Astrana Health (ASTH) to $86 from $67 and keeps an Outperform rating on the shares. The firm said the company’s largest acquisition to date, Prospect Health, adds incredible firepower to the company’s already-attractive long-term full-risk conversion story.